Themis Medicare Share Price

Pharmaceuticals company Themis Medicare announced Q4FY26 & FY26 results Q4FY26 Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 7,653.05 lakh in Q4FY26, registering a growth of 6.73% YoY compared to Rs 7,170.16 lakh in Q4FY25. On a QoQ basis, it witnessed a decline of 15.09% from Rs 9,013.32 lakh in Q3FY26. Total Income: Reported at Rs 8,019.75 lakh in Q4FY26, marking an increase of 9.48% YoY against Rs 7,325.35 lakh in Q4FY25, but a decrease of 12.27% QoQ compared to Rs 9,141.55 lakh in Q3FY26. Profit for the Period (PAT): Reached Rs 888.54 lakh in Q4FY26, showing a strong turnaround from a loss of Rs 966.45 lakh in Q4FY25. Sequentially, PAT declined by 11.97% QoQ from Rs 1,009.36 lakh in Q3FY26. FY26 Consolidated Financial Highlights: Revenue from Operations: Recorded at Rs 34,223.55 lakh for FY26, reflecting a decline of 15.60% YoY compared to Rs 40,551.16 lakh in FY25. Total Income: Stood at Rs 35,159.71 lakh in FY26, a decrease of 14.28% YoY from Rs 41,018.11 lakh in FY25. Profit for the Period (PAT): Plunged by 96.17% YoY to Rs 114.37 lakh in FY26, down from a profit of Rs 2,983.28 lakh in FY25. Q4FY26 Standalone Financial Highlights: Revenue from Operations: Stood at Rs 7,653.05 lakh in Q4FY26, an increase of 6.73% YoY compared to Rs 7,170.16 lakh in Q4FY25, but down by 15.09% QoQ from Rs 9,013.32 lakh in Q3FY26. Total Income: Was Rs 8,019.75 lakh in Q4FY26, reflecting a YoY growth of 9.48% from Rs 7,325.35 lakh in Q4FY25. On a QoQ basis, it decreased by 12.27% from Rs 9,141.55 lakh in Q3FY26. Profit for the Period (PAT): Reported a profit of Rs 196.56 lakh in Q4FY26, recovering from a loss of Rs 774.48 lakh in Q4FY25. However, it saw a QoQ decline of 57.07% from Rs 457.81 lakh in Q3FY26. FY26 Standalone Financial Highlights: Revenue from Operations: Reached Rs 34,223.55 lakh for FY26, marking a decrease of 15.60% YoY from Rs 40,551.16 lakh in FY25. Total Income: Stood at Rs 35,159.71 lakh in FY26, a drop of 14.28% YoY compared to Rs 41,018.11 lakh in FY25. Profit for the Period (PAT): The company reported a net loss of Rs 1,418.55 lakh in FY26, sliding from a net profit of Rs 2,392.15 lakh reported in FY25. Business Highlights: Segment Performance: The Company operates in a single business segment, i.e., Pharmaceuticals, and hence does not have any separately reportable business segments. Dividend Recommendation: The Board of Directors has recommended a final dividend of Re 0.50 per fully paid-up equity share (50% on the face value of Re 1/- each), aggregating to Rs 4,60,50,060 for the financial year ended 31st March, 2026, subject to the approval of shareholders. Exceptional Items: The company presented an incremental regulatory impact of Rs 86.53 lakh under Exceptional Items in its Q3FY26 results due to changes in the new Labour Codes. Additionally, in the standalone results, an exceptional item of Rs 129.39 lakh was noted, relating to investments, receivables, and advances for its wholly-owned dissolved UK subsidiary, M/s. Carpo Medicals Limited, which the company is in the process of writing off pending RBI approval. Result PDF

• Trendlyne
• 2 weeks 6 days ago

Pharmaceuticals company Themis Medicare announced Q2FY26 results Revenue: Rs 78.0 crore against Rs 117.0 crore during Q2FY25. EBITDA: Rs -3.1 crore against Rs 17.1 crore during Q2FY25. EBITDA Margin: -4.0% for Q2FY26. PAT: Rs -3.6 crore against Rs 14.3 crore during Q2FY25. PAT Margin: -4.6% for Q2FY26. EPS: Rs -0.39 for Q2FY26. Sachin Patel, Managing Director & CEO, said: “The Company continued to face headwinds from disruption in a high margin major line of Business since the last two quarters. In this regard, regulators are currently investigating the matter and we expect a positive development on this by March 2026. Despite the headwinds, our API business grew 31% year-on-year in the half-year period, while Trade business increased 4%. As part of our Hospital business, we aim to increase our focus on high margin brands and products. Moving forward, we are striving to improve operational efficiency, cost optimization, field force productivity, and working capital management. Our R&D; pipeline continues to be strong, and we will keep directing our efforts into creating differentiated products in critical therapeutic areas. Consolidated revenue for the quarter was reported at Rs 78 crore; muted performance in the formulations business hampered profitability. The Company remains resilient and we are cautiously optimistic based on our core competence and overall market opportunity.” Result PDF

• Trendlyne
• 7 months 1 week ago

Management also notified that they have incorporated their wholly-owned subsidiary in the name of Rx Themis Private Limited.'

• Moneycontrol
• 2 years 9 months ago